Novartis: In need of ‘calcium sandoz’ - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Novartis: In need of ‘calcium sandoz’

Dec 8, 2000

Novartis held an analyst meet yesterday to apprise investors of the latest developments after the hive off the agri business operations. The management announced a takeover of the Ciba CKD, a joint venture with a Korean company, elaborated on the realignment of its ophthalmic business and expressed its intent to divest the remaining portion of its Goregaon (a Mumbai suburb) property. Ciba CKD was a joint venture between Novartis India and Chong Kuon Dang (Korea) for the manufacture of rifampicin, an anti–TB bulk drug. The company bought out the Korean partner’s stake at a price of Rs 7.48 per share. The reasoning for this buyout was the fact that anti–TB is an important therapeutic area for the company (it contributes almost 8% to the company’s turnover) and the management felt that the collaboration was not working out. The management, however, was not willing to specify whether it would merge Ciba CKD with Novartis India in the future.

As far as the divestment of the property is concerned, the management has appointed a real estate consultant Knight Frank to manage the sale. In the current year, the company gave the development rights for a part of the property to Kingston Properties for a price of Rs 66 m. The management did clarify that a part of the property (297,000 square metres of surface area) does face various reservations being in a non–industrial zone and certain rights belong to Ciba Specialties, which was also a part of the erstwhile Hindustan Ciba Geigy.

As far as the realignment of the ophthalmic business is concerned, the business now forms a part of the pharmaceutical business under Mr. Ranjit Shahani. This business, was earlier clubbed with the contact lens business, and was part of Ciba Vision.

As far as the pharmaceutical business goes, the company has plans to introduce four brands Coartem (an anti–malarial), Zometa (anti–cancer), Visodyne (a sight saving product) and Miacalcic (osteoporosis). However, the company’s top brand Voveran (an anti–inflammatory), which contributed almost 18% to Novartis’ turnover, seems to be facing a slowdown, although the management denies it. It’s immuno–suppressant brand Sandimune (which contributes over 12% to Novartis’ turnover) has also been slapped with a 15% import duty, which has raised its costs by 40%. Overall, FY01 is likely to be tough one for Novartis as far as topline growth is concerned and this explains the relatively lower earnings multiple (23X FY01 earnings) vis-ŕ-vis the other MNC pharma companies.

Equitymaster requests your view! Post a comment on "Novartis: In need of ‘calcium sandoz’". Click here!

  

More Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Dec 1, 2021 03:36 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS